In short: Total Quality Score 8.0/10, at $83.9 and a $1.9bn market cap. "One of the best compounders you've never heard of… While others looked elsewhere, LeMaitre compounded quietly and massively outperformed the S&P 500" — $10,000 → $161,460 since the 2006 IPO (15.5% CAGR) versus $98,690 for the index. Classified as an Owner-Operator: founded 1983 by vascular surgeon George D. LeMaitre after he invented a new valvulotome, run since 2004 by his son George W. LeMaitre, with insiders still holding 8.1%. The moat is niche economics plus regulation — "too small for the giants, but too complex for generic manufacturers", and "once LeMaitre's devices are in the Operator Room, they tend to stay there." Quality metrics: gross margin 71.0%, ROIC 21.3%, net margin 22.1%, FCF/net income 124.2%, net cash, goodwill 11.0% of assets, CAPEX 2.9% of sales; revenue +14.6% / EPS +20.6% a year over five years; Owner's Earnings +21.6% (5yr) and +20.3% (10yr). Three failures are recorded rather than argued away: ROE 14.9% (bar >20%), SBC 14.0% of net income, 15.6% on a five-year average (bar <10%), and a reverse DCF demanding 16.1% FCF growth for ten years — flagged as unrealistic. Valuation splits two-to-one in favour: 32.5x forward against a 38.0x ten-year average, an Earnings Growth Model return of 11.7% (13% EPS growth + 1% yield, multiple fading 32.5x → 25.0x). Verdict: "Lemaitre Vascular is an amazing company. It's the perfect example of a Tiny Titan" — a small-cap idea, with no purchase, target price or portfolio decision attached.
LeMaitre makes the instruments and implants surgeons use when they operate on blood vessels in the legs, arms and neck — the arteries and veins outside the heart and brain. Grafts to replace a damaged section of vessel, patches to close one, balloons to open a blockage, and the small tool the founder invented in 1983 to cut open stuck valves inside veins. Over a hundred products, sold straight to hospitals.
It has done this quietly and very well: $10,000 put in at the 2006 flotation would be $161,460 today against $98,690 in the S&P 500, and it is still only a $1.9 billion company.
The reason it can earn 71 cents of gross profit on every dollar of sales is the shape of its market rather than any single clever product. Peripheral vascular surgery is too small a business for Medtronic or Boston Scientific to bother fighting over, and too specialised and too regulated for a cheap generic manufacturer to enter — every device needs years of approvals, and a hospital that changes supplier has to retest everything and retrain its surgeons on something that can kill a patient if it fails. So once a LeMaitre device is in the operating room it tends to stay there. On top of that the company keeps buying up small rivals — more than 30 so far — and pushes their products through its own 100-person salesforce, which is worth far more inside LeMaitre than it was outside.
Slegers runs it through his fifteen-question checklist and it passes twelve of them, scoring 8.0 out of 10. What it fails on is worth knowing. Staff are paid in shares worth about 15% of profits — a real cost to existing owners, and above his 10% limit. Return on equity is 14.9%, below his 20% bar. And most importantly, his reverse calculation says the current share price already assumes the company's cash flow grows 16% a year for the next decade, which he marks as unrealistic. Against that, the shares are cheaper than their own ten-year average and his return model gets to 11.7% a year.
So: an excellent, genuinely obscure business, priced as though the good news continues without interruption — and a piece written for the closed small-cap service, not as a candidate for the main portfolio. The article asks "should you buy?" in the title and never answers it, which is itself the honest signal.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.